Annemans L - Search Results

1

Economic Evaluation of Vaccines: Belgian Reflections on the Need for a Broader Perspective.

Annemans L, Beutels P, Bloom DE, De Backer W, Ethgen O, Luyten J, Van Wilder P, Willem L, Simoens S. Annemans L, et al. Value Health. 2021 Jan;24(1):105-111. doi: 10.1016/j.jval.2020.09.005. Epub 2020 Dec 11. Value Health. 2021. PMID: 33431141 Free article.

2

Modeling costs and cost-effectiveness of different CMV management strategies in liver transplant recipients as a support for current and future decision making.

Annemans L, Moeremans K, Mutimer D, Schneeberger H, Milligan D, Kubin M. Annemans L, et al. Value Health. 2002 Jul-Aug;5(4):347-58. doi: 10.1046/j.1524-4733.2002.54117.x. Value Health. 2002. PMID: 12102697 Free article.

3

Cost-effectiveness analysis of bicalutamide (Casodex) for adjuvant treatment of early prostate cancer.

Moeremans K, Caekelbergh K, Annemans L. Moeremans K, et al. Among authors: annemans l. Value Health. 2004 Jul-Aug;7(4):472-81. doi: 10.1111/j.1524-4733.2004.74010.x. Value Health. 2004. PMID: 15449639 Free article.

4

Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases.

Bos JM, Beutels P, Annemans L, Postma MJ. Bos JM, et al. Among authors: annemans l. Pharmacoeconomics. 2004;22(18):1171-9. doi: 10.2165/00019053-200422180-00002. Pharmacoeconomics. 2004. PMID: 15606224 Review.

5

A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.

Lamotte M, Annemans L, Evers T, Kubin M. Lamotte M, et al. Among authors: annemans l. Pharmacoeconomics. 2006;24(2):155-69. doi: 10.2165/00019053-200624020-00005. Pharmacoeconomics. 2006. PMID: 16460136

6

Early modelling for assessing health and economic outcomes of drug therapy.

Annemans L, Genesté B, Jolain B. Annemans L, et al. Value Health. 2000 Nov-Dec;3(6):427-34. doi: 10.1046/j.1524-4733.2000.36007.x. Value Health. 2000. PMID: 16464202 Free article.

7

An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy.

Annemans L, Demarteau N, Hu S, Lee TJ, Morad Z, Supaporn T, Yang WC, Palmer AJ. Annemans L, et al. Value Health. 2008 May-Jun;11(3):354-64. doi: 10.1111/j.1524-4733.2007.00250.x. Epub 2007 Sep 21. Value Health. 2008. PMID: 17888064 Free article.

8

Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: a need for improved modelling to aid decision making.

Annemans L. Annemans L. Pharmacoeconomics. 2008;26(5):409-23. doi: 10.2165/00019053-200826050-00005. Pharmacoeconomics. 2008. PMID: 18429657 Review.

9

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

Annemans L, Rémy V, Oyee J, Largeron N. Annemans L, et al. Pharmacoeconomics. 2009;27(3):231-45. doi: 10.2165/00019053-200927030-00006. Pharmacoeconomics. 2009. PMID: 19354343

10

Stimulating pharmaceutical innovation in the EU.

Annemans L, Cleemput I, Hulstaert F, Simoens S. Annemans L, et al. Expert Rev Pharmacoecon Outcomes Res. 2011 Jun;11(3):235-9. doi: 10.1586/erp.11.19. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 21671690 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

378 results

Search Page

Filters